<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260513069381N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-09</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Clinical Outcomes  of open and laparoscopic surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Clinical Outcomes  of open and laparoscopic surgery among pediatric patients with hydatid cysts: A randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/90098</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The unit of randomization in this study will be the individual patient. Eligible patients will be randomly allocated to two groups using balanced permuted block randomization: the intervention group (laparoscopic surgery) and the control group (open surgery). The random allocation sequence will be generated using Stata version 14 by an independent epidemiologist who will not be involved in patient recruitment, delivery of the interventions, or outcome assessment.
Fixed block sizes of four will be used, with two patients allocated to each treatment group within each block. The order of assignments within each block will be determined randomly. A total of five blocks will be generated to randomize the planned sample of 20 patients.
To ensure allocation concealment, the randomization sequence generated by the independent epidemiologist will be placed in sequentially numbered, opaque, sealed envelopes (SNOSE). The envelopes will be opened sequentially, in numerical order, only after a patient has been confirmed to meet the eligibility criteria and has been enrolled in the study. This procedure will prevent the upcoming treatment allocation from being revealed or predicted before the patient's assignment. The epidemiologist responsible for generating the randomization sequence will have no involvement in patient recruitment or the surgical procedures, Blinding description: The outcome assessor will not be present in the operating room during the surgical procedures. Following each surgery, the outcomes of interest will be assessed by extracting the relevant information from the patient's medical records and operative documentation. The outcome assessor will be blinded to the type of surgical procedure performed and will therefore be unaware of whether the patient underwent laparoscopic or open surgery. The statistical analyst will also remain blinded to treatment allocation throughout the data analysis process. In the statistical datasets and analysis software, the two study groups will be coded as Group A and Group B. The identity of the treatment groups will remain concealed from the statistical analyst until completion of the primary statistical analyses.</study_design>
      <phase>3</phase>
      <hc_freetext>Hydatid cysts.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this group, minimally invasive laparoscopic surgery will be performed in children with hepatic hydatid cysts by a single surgeon. Intervention 2: Control group: In the control group, open surgery will be performed in patients with the same condition and identical surgical indications.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Individual participant data will be made available after removing all direct and indirect identifiers, upon reasonable request and subject to ethical and confidentiality considerations. The data will be provided only to qualified researchers for valid scientific and research purposes and following review and approval of the request. The shared dataset will not contain names, national identification numbers, hospital record numbers, telephone numbers, addresses, or any other information that could directly or indirectly identify the participants.

When:
Access to the de-identified study documents and data files will begin 6 months after publication of the primary results of the study and will remain available for 5 years from the date access begins.

To whom:
The study data and supporting documents will be available upon request to qualified researchers affiliated with universities, research institutions, or other recognized academic and scientific organizations. Requests must be submitted for valid scientific research purposes and will be reviewed and approved before access to the de-identified data is granted.

Conditions:
Access to the data and supporting documents will be granted only for valid scientific research purposes. Applicants must specify the research objective, research question, and general analytical approach in their request. Only de-identified data will be provided, and recipients must maintain data confidentiality and security and must not share the data with third parties. Any attempt to re-identify participants will be strictly prohibited. The data must be used in accordance with applicable ethical and research regulations and only for the purposes approved in the request. Requests will be reviewed and approved by the study investigators before access is granted. Any publication resulting from the use of the shared data must appropriately acknowledge and cite the original study. Any proposed use beyond the scope of the original request will require a new request and additional approval.

Where to obtain:
Applicants may submit requests for access to the de-identified study data and supporting documents directly to the principal investigator via the investigator’s official institutional email address. The request should include the applicant’s name and institutional affiliation, the purpose of the proposed research, the research question or objectives, and the general analytical approach. Requests will be reviewed by the study investigators and, if the specified eligibility criteria are met, will be processed through the same communication channel, with the requested data provided through a secure data-transfer mechanism. Contact information for the principal investigator: [Ebrahim Farhadi], Department of Pediatric Surgery, Tabriz University of Medical Sciences, Tabriz, Iran; Email: [ibrahim.farhadi96@gmail.com].

How to obtain:
Applicants must submit their request via the official email address of the principal investigator. The request must include the applicant’s contact information, institutional affiliation, research purpose and question, general analytical approach, and intended use of the requested data. Each complete request will be reviewed within 14 business days to assess the completeness of the information and compliance with the data-access requirements. If additional information or documentation is required, the applicant will be contacted and asked to provide the necessary materials. Once the request is approved, the de-identified data and approved supporting documents will be provided to the applicant through a secure data-transfer mechanism within 30 business days of final approval. If a request is denied, the applicant will be informed of the decision and the reason for denial by email. The entire process, from receipt of a complete request to provision of the requested data, is expected to take no more than 44 business days.

Comments:
No additional information is required at this time. Any data sharing will be conducted in accordance with applicable ethical requirements, participant confidentiality protections, and the data-access procedures and conditions described above.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ebrahim Farhadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tabriz University of Medical Sciences, Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5165665931</zip>
        <telephone>+98 41 3335 5921</telephone>
        <email>ibrahim.farhadi96@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ebrahim Farhadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tabriz University of Medical Sciences, Golgasht Street</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5165665931</zip>
        <telephone>+98 41 3335 5921</telephone>
        <email>ibrahim.farhadi96@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age range between 2 - 18 years
Clinical indication for open or laparoscopic surgery</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Ruptured cysts
Cysts near the vessels
Contraindications to laparoscopy
Patients with a history of malignancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B67.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Echinococcus granulosus infection of liver</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this group, minimally invasive laparoscopic surgery will be performed in children with hepatic hydatid cysts by a single surgeon.</i_keyword>
      <i_keyword>Control group: In the control group, open surgery will be performed in patients with the same condition and identical surgical indications.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The primary outcome of the study will be the comparison of surgical time/duration between groups. Timepoint: Length of hospital stay. Method of measurement: Medical recorda and clinical observations in the surgery.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Secondary outcomes will include surgical complications such as infection, recurrence, ulceration, pain intensity, and other clinical and paraclinical manifestations between the two methods. Timepoint: At postoperative days 0 and 3, and at one week and one month following surgery. Method of measurement: Infection, recurrence, and ulceration will be assessed based on clinical observation by the surgeon, and pain intensity will be measured using the Visual Analog Scale (VAS).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-09-16</approval_date>
        <contact_name>Ethics Committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
